Headache; Start of mild signs random located rash/rash become severe on face and neck /rash moved and severely affected my back; soreness in neck and upper back; intense sore ness in neck; Intense fatigue; Ache than a sharp pain; First night - 101F fever. After Second night in the morning: Intense soreness in neck and upper back in the morning. I had to stay laying down. The pain was more of an intense fatigue and ache than a; This is a spontaneous report from a contactable consumer, the patient. A 24-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER7534) via an unspecified route of administration in the right arm on 24Mar2021 at 09:45 (at the age of 24-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included herbal allergy medication (MANUFACTURER UNKNOWN) from an unknown date for unknown indication and unknown if ongoing. On 24Mar2021 at 23:45, first night after vaccination, the patient experienced 101F fever. On 26Mar2021, after second night in the morning: intense soreness in neck and upper back in the morning, the patient had to stay laying down. The pain was more of an intense fatigue and ache than a sharp pain. Start of mild signs random located rash. On, third day: alright for the most part. On 27Mar2021, fourth day: morning, the sharper type of sore in neck and back after waking. Intense, midday headache. Evening, rash become severe on face and neck. On fifth day evening: Rash severe on face. After ointment applied on face, rash moved and severely affected my back. After applying more ointment, rash moved again. However, applying more medication has helped. On fifth day: rash still present all over face, neck, and head but not as itchy. (It is the fifth day today). On 24Mar2021, the patient underwent body temperature test and the result was 101 degrees Fahrenheit. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events rash on head, face and neck which included treatment with ointment and medication (unspecified). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events, 101F fever, intense soreness in neck and upper back, intense fatigue and ache, mild signs random located rash, sharper type of sore in neck and back after waking, intense, midday headache, rash become severe on face and neck, rash severe on face, rash moved and severely affected back, rash still present all over face, neck, and head but not as itchy was recovering at the time of this report. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729,) via an unspecified route of administration in the left arm on 14Apr2021 at 09:45 (at the age of 24-year-old) as a single dose for COVID-19 immunisation.  No follow-up attempts are needed. No further information is expected.